Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial.
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
05
2021
revised:
09
06
2021
accepted:
10
06
2021
pubmed:
6
7
2021
medline:
6
7
2021
entrez:
5
7
2021
Statut:
ppublish
Résumé
Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19. We conducted a pilot randomized, open-label, controlled, phase 2 trial at two hospitals in France. Eligible patients were consecutive outpatients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and an interval from symptom onset to enrolment of 7 days or less. Patients were randomly assigned in a 1:1 ratio to receive oral tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7) or the standard of care. The primary and secondary endpoints were SARS-CoV-2 viral clearance from baseline assessed by cycle threshold (Ct) RT-PCR on nasopharyngeal swab collected at day 4 and day 7, respectively. A higher Ct corresponds to a lower SARS CoV-2 viral burden. Other endpoints were the time to recovery and the number of adverse events. This trial is registered with ClinicalTrials.gov, NCT04685512. From November, 20 In this pilot study of outpatients adult with recent non-severe COVID-19, tenofovir disoproxil fumarate plus emtricitabine appeared to accelerate the natural clearance of nasopharyngeal SARS-CoV-2 viral burden. These findings support the conduct of larger trials of tenofovir-based therapies for the prevention and early treatment of COVID-19. No external funding.
Sections du résumé
BACKGROUND
BACKGROUND
Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19.
METHODS
METHODS
We conducted a pilot randomized, open-label, controlled, phase 2 trial at two hospitals in France. Eligible patients were consecutive outpatients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and an interval from symptom onset to enrolment of 7 days or less. Patients were randomly assigned in a 1:1 ratio to receive oral tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7) or the standard of care. The primary and secondary endpoints were SARS-CoV-2 viral clearance from baseline assessed by cycle threshold (Ct) RT-PCR on nasopharyngeal swab collected at day 4 and day 7, respectively. A higher Ct corresponds to a lower SARS CoV-2 viral burden. Other endpoints were the time to recovery and the number of adverse events. This trial is registered with ClinicalTrials.gov, NCT04685512.
FINDINGS
RESULTS
From November, 20
INTERPRETATION
CONCLUSIONS
In this pilot study of outpatients adult with recent non-severe COVID-19, tenofovir disoproxil fumarate plus emtricitabine appeared to accelerate the natural clearance of nasopharyngeal SARS-CoV-2 viral burden. These findings support the conduct of larger trials of tenofovir-based therapies for the prevention and early treatment of COVID-19.
FUNDING
BACKGROUND
No external funding.
Identifiants
pubmed: 34222849
doi: 10.1016/j.eclinm.2021.100993
pii: S2589-5370(21)00273-X
pmc: PMC8235994
doi:
Banques de données
ClinicalTrials.gov
['NCT04685512']
Types de publication
Journal Article
Langues
eng
Pagination
100993Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
J.-JP reports personal fees and grant support from Gilead Sciences, Merck Sharp & Dohme and ViiV Healthcare outside the submitted work. L.H. reports personal fees and non-financial support from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare outside the submitted work. Other authors declare no competing interests.
Références
PLoS One. 2010 Jun 10;5(6):e11068
pubmed: 20548786
Stat Methods Med Res. 1993;2(1):23-41
pubmed: 8261248
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Clin Infect Dis. 2020 Jul 16;:
pubmed: 32674126
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Antimicrob Agents Chemother. 2001 Dec;45(12):3381-6
pubmed: 11709312
Epidemiology. 2020 Nov;31(6):e49-e51
pubmed: 32773469
Open Forum Infect Dis. 2020 Sep 25;7(11):ofaa455
pubmed: 33200081
Clin Infect Dis. 2009 Feb 15;48(4):484-8
pubmed: 19140758
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451
PLoS One. 2020 Dec 23;15(12):e0242398
pubmed: 33362283
Antimicrob Agents Chemother. 2005 May;49(5):1898-906
pubmed: 15855512
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Clin Infect Dis. 2020 Aug 29;:
pubmed: 32860699
Ann Intern Med. 2020 Oct 20;173(8):623-631
pubmed: 32673060
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):265-75
pubmed: 21471820
Drug Saf. 2020 Dec;43(12):1309-1314
pubmed: 32978702
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):495-501
pubmed: 25763783
N Engl J Med. 2020 Oct 29;383(18):e101
pubmed: 32897661
Int J Infect Dis. 2020 Dec;101:49-51
pubmed: 32987182
mBio. 2020 May 22;11(3):
pubmed: 32444382
J Proteome Res. 2020 Nov 6;19(11):4690-4697
pubmed: 32692185
Am J Epidemiol. 2021 Apr 13;:
pubmed: 33847737
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
J Acquir Immune Defic Syndr. 2020 Oct 1;85(2):123-126
pubmed: 32675771
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
Cold Spring Harb Perspect Biol. 2011 Oct 01;3(10):a004820
pubmed: 21628428
AIDS. 2021 Jul 15;35(9):1509-1511
pubmed: 33710026
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Antimicrob Agents Chemother. 2020 Dec 16;65(1):
pubmed: 33122172
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463